C4 Therapeutics, Inc. Basic Shares Outstanding (Weighted Average)
C4 Therapeutics, Inc. (CCCC) reported Basic Shares Outstanding (Weighted Average) of 130.70 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-08-11
- C4 Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 130.70M shares, a 84.07% increase year-over-year.
- C4 Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 126.07M shares, a 77.99% increase year-over-year.
- C4 Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 117.16M shares, a 65.91% increase year-over-year.
- C4 Therapeutics, Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 72.56M shares, a 4.22% increase year-over-year.
- C4 Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 82.89M shares, a 19.49% increase from fiscal 2024.
- C4 Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 69.37M shares, a 39.75% increase from fiscal 2023.
- C4 Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 49.64M shares, a 1.59% increase from fiscal 2022.
- C4 Therapeutics, Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 48.86M shares, a 6.12% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | 130.70M shares 10-Q · filed 2026-08-11 | 128.40M shares 10-Q · filed 2026-08-11 | 124.64M shares derived: average of 3 quarters · filed 2026-08-11 | 111.62M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 126.07M shares 10-Q · filed 2026-05-12 | 121.62M shares derived: average of 2 quarters · filed 2026-05-12 | 105.26M shares derived: average of 3 quarters · filed 2026-05-12 | 96.70M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | 117.16M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 94.86M shares derived: average of 2 quarters · filed 2026-02-26 | 86.91M shares derived: average of 3 quarters · filed 2026-08-11 | 82.89M shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 72.56M shares 10-Q · filed 2025-11-06 | 71.78M shares derived: average of 2 quarters · filed 2026-08-11 | 71.47M shares 10-Q · filed 2025-11-06 | 71.25M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | 71.01M shares 10-Q · filed 2026-08-11 | 70.92M shares 10-Q · filed 2026-08-11 | 70.82M shares derived: average of 3 quarters · filed 2026-08-11 | 70.52M shares derived: average of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | 70.83M shares 10-Q · filed 2026-05-12 | 70.72M shares derived: average of 2 quarters · filed 2026-05-12 | 70.36M shares derived: average of 3 quarters · filed 2026-05-12 | 69.97M shares derived: average of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | 70.62M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 70.12M shares derived: average of 2 quarters · filed 2026-02-26 | 69.68M shares derived: average of 3 quarters · filed 2026-02-26 | 69.37M shares 10-K · filed 2026-02-26 |
| 2024-09-30 | 69.63M shares 10-Q · filed 2025-11-06 | 69.22M shares derived: average of 2 quarters · filed 2025-11-06 | 68.96M shares 10-Q · filed 2025-11-06 | 64.53M shares derived: average of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | 68.81M shares 10-Q · filed 2025-08-07 | 68.62M shares 10-Q · filed 2025-08-07 | 62.83M shares derived: average of 3 quarters · filed 2025-08-07 | 59.43M shares derived: average of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | 68.43M shares 10-Q · filed 2025-05-07 | 59.84M shares derived: average of 2 quarters · filed 2025-05-07 | 56.30M shares derived: average of 3 quarters · filed 2025-05-07 | 54.49M shares derived: average of 4 quarters · filed 2025-05-07 |
| 2023-12-31 | 51.25M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 50.23M shares derived: average of 2 quarters · filed 2025-02-27 | 49.84M shares derived: average of 3 quarters · filed 2025-02-27 | 49.64M shares 10-K · filed 2025-02-27 |
| 2023-09-30 | 49.21M shares 10-Q · filed 2024-10-31 | 49.14M shares derived: average of 2 quarters · filed 2024-10-31 | 49.10M shares 10-Q · filed 2024-10-31 | 49.07M shares derived: average of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | 49.06M shares 10-Q · filed 2024-08-01 | 49.05M shares 10-Q · filed 2024-08-01 | 49.02M shares derived: average of 3 quarters · filed 2024-08-01 | 49.00M shares derived: average of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | 49.03M shares 10-Q · filed 2024-05-08 | 49.00M shares derived: average of 2 quarters · filed 2024-05-08 | 48.97M shares derived: average of 3 quarters · filed 2024-05-08 | 48.94M shares derived: average of 4 quarters · filed 2024-05-08 |
| 2022-12-31 | 48.96M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | 48.94M shares derived: average of 2 quarters · filed 2024-02-22 | 48.90M shares derived: average of 3 quarters · filed 2024-02-22 | 48.86M shares 10-K · filed 2024-02-22 |
| 2022-09-30 | 48.92M shares 10-Q · filed 2023-11-01 | 48.87M shares derived: average of 2 quarters · filed 2023-11-01 | 48.83M shares 10-Q · filed 2023-11-01 | 48.79M shares derived: average of 4 quarters · filed 2023-11-01 |
| 2022-06-30 | 48.82M shares 10-Q · filed 2023-08-08 | 48.78M shares 10-Q · filed 2023-08-08 | 48.75M shares derived: average of 3 quarters · filed 2023-08-08 | 48.68M shares derived: average of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | 48.73M shares 10-Q · filed 2023-05-04 | 48.71M shares derived: average of 2 quarters · filed 2023-05-04 | 48.63M shares derived: average of 3 quarters · filed 2023-05-04 | 47.44M shares derived: average of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | 48.68M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | 48.58M shares derived: average of 2 quarters · filed 2023-02-23 | 47.01M shares derived: average of 3 quarters · filed 2023-02-23 | 46.04M shares 10-K · filed 2023-02-23 |
| 2021-09-30 | 48.49M shares 10-Q · filed 2022-11-03 | 46.17M shares derived: average of 2 quarters · filed 2022-11-03 | 45.16M shares 10-Q · filed 2022-11-03 | |
| 2021-06-30 | 43.86M shares 10-Q · filed 2022-08-04 | 43.47M shares 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |